Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock Has Consensus Target Price of $48.00

Posted by Stanley Muller on Nov 10th, 2026

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Free Report) has earned a consensus rating of “Moderate Buy” from the thirteen brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $48.00.

A number of research firms recently commented on HRMY. UBS Group reiterated a “neutral” rating and issued a $37.00 target price on shares of Harmony Biosciences in a research note on Wednesday, August 5th. WBB Securities upgraded shares of Harmony Biosciences to a “hold” rating in a research note on Friday, October 23rd. Zacks Research raised shares of Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 15th. Needham & Company LLC reiterated a “buy” rating and set a $50.00 price objective on shares of Harmony Biosciences in a research note on Monday, October 19th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $42.00 price objective on shares of Harmony Biosciences in a research note on Thursday, October 1st.

Check Out Our Latest Stock Analysis on HRMY

Harmony Biosciences Trading Up 2.0%

Harmony Biosciences stock opened at $33.78 on Tuesday. The stock has a 50-day moving average of $39.25 and a two-hundred day moving average of $34.69. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.45 and a current ratio of 3.44. Harmony Biosciences has a one year low of $25.90 and a one year high of $43.49. The stock has a market cap of $1.97 billion, a PE ratio of 11.19, a price-to-earnings-growth ratio of 0.28 and a beta of 1.00.

Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.81 earnings per share for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.28). Harmony Biosciences had a return on equity of 18.55% and a net margin of 18.05%. The business had revenue of $268.92 million for the quarter, compared to analysts’ expectations of $272.05 million. During the same quarter in the previous year, the firm posted $1.08 EPS. Harmony Biosciences’s revenue was up 12.3% on a year-over-year basis. On average, research analysts anticipate that Harmony Biosciences will post 3.69 EPS for the current fiscal year.

Insider Transactions at Harmony Biosciences

In other Harmony Biosciences news, insider Kumar Budur sold 35,852 shares of Harmony Biosciences stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $43.05, for a total transaction of $1,543,428.60. Following the completion of the sale, the insider owned 13,115 shares of the company’s stock, valued at approximately $564,600.75. The trade was a 73.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last ninety days, insiders sold 72,406 shares of company stock valued at $3,108,520. Company insiders own 11.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Farther Finance Advisors LLC boosted its position in Harmony Biosciences by 166.7% in the third quarter. Farther Finance Advisors LLC now owns 816 shares of the company’s stock valued at $32,000 after buying an additional 510 shares during the last quarter. Nykredit A S purchased a new position in Harmony Biosciences during the 2nd quarter worth approximately $33,000. Signature Equity Partners LLC purchased a new position in Harmony Biosciences during the 3rd quarter worth approximately $37,000. Hantz Financial Services Inc. raised its position in Harmony Biosciences by 32.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,401 shares of the company’s stock worth $55,000 after buying an additional 345 shares during the last quarter. Finally, Integrated Wealth Concepts LLC acquired a new stake in Harmony Biosciences during the 2nd quarter valued at approximately $65,000. 86.23% of the stock is currently owned by hedge funds and other institutional investors.

Harmony Biosciences Company Profile

(Get Free Report)

Harmony Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for people living with rare neurological diseases. The company’s work centers on therapies intended to address significant unmet medical needs.

Its lead product, WAKIX (pitolisant), is approved in the United States to treat excessive daytime sleepiness or cataplexy in adults and pediatric patients aged 6 years and older with narcolepsy. Harmony launched WAKIX in the United States in 2019.

Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony primarily serves the U.S.